Inhalation Sciences Sweden AB (publ) announced that it has now received the formal clearance to begin the experimental phase of the study. The study is now commencing at the company's facilities in Sweden. The objective of contract 75F40122C00197 is to evaluate the discriminative power of ISAB's Dissolv It technology by comparing drug formulations, aimed for administration via inhalation, with small differences.

The project scope also includes in vitro-in vivo correlation (IVIVC) efforts. The proposed work was approved by the FDA Center for Drug Evaluation and Research (CDER). This research project is planned to be finalized by September 2024.